Mental Health DailyResearch. Evidence. Perspective.Published research on lecanemab.
A 2026 review in the Japanese Journal of Radiology argued that amyloid PET has moved from an optional Alzheimer’s disease biomarker to a practical eligibility gate for anti-amyloid antibody …
Read articleLecanemab blood biomarkers may rebound much faster than amyloid PET after treatment stops: a 2026 PK/PD model estimated that half of the Aβ42/40 treatment effect is lost within 0.5 years, co…
Read articleA 2026 Nature Neuroscience study found that lecanemab cleared amyloid in a humanized-microglia Alzheimer’s disease model only when microglia and the antibody’s intact Fc fragment were both p…
Read articleUntil recently, Alzheimer’s pathology could only be confirmed in living patients via PET imaging or lumbar puncture. Plasma p-tau217 changed that calculus — but how to interpret a positive r…
Read article
